Company: CYTK
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013167
Chunk: 71

Company: CYTOKINETICS INC
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 71
---
 in place; Global PRMA and launch sequence strategy in place; and |

| • | Continue to develop HERO data generation to support value proposition for aficamten. |

| • | Goals attributable to Aficamten U.S. Launch Readiness: |

| • | Initiate Launch Readiness activities; |

| • | Establish Market Development campaign; |

| • | Commercialization strategy established; initiate build-out of distribution network; and |

| • | Field deployment model finalized and approved. |

| • | Goals attributable to Commercial Portfolio Prioritization: |

| • | In partnership with R&D, operationalize the portfolio prioritization process to support molecule development programs and lifecycle plans; |

| • | CK-586: leadership endorsed lead indication selection, competitive positioning and market opportunity at Phase 2 decision gate inclusive of the Phase 3 development plan; |

| • | Omecamtiv Mecarbil: Drive Board decision on second study supported by data analytics; and |

| • | Aficamten: Create business cases for potential additional life cycle management opportunities. |

| • | Goals attributable to Commitment to Culture of Compliance: |

| • | 100% commercial employees complete Master Control and all compliance training within allotted time frame; |

| • | Commercial spend within 5% of board approved 2024 external spend budget; |

| • | Deploy financial training to commercial organization with active monitoring plan; |

| • | Automate and deploy field monitoring and ensure ongoing compliance course correction with quarterly scorecard to include ride-alongs and audits; and |

| • | Zero percent compliance incidents. |

| Cytokinetics, Inc.|2025 Proxy Statement |     | 49 |

TABLE OF CONTENTS Executive Compensation

| • | Personal development and leadership goals. |

| • | Dr. Malik’s individual goals for 2024 included: |

| • | Goals attributable to the development of Aficamten: |

| • | Present and publish the main results from SEQUOIA-HCM; |

| • | Complete enrollment in MAPLE-HCM; |

| • | Specific site activation and patient enrollment targets in connection with ACACIA-HCM; |

| • | Complete pre-submission meetings with FDA and EMA; and |

| • | Submit marketing applications for aficamten in the US, EU and China. |

| • | Goals attributable to the development of CK-586: |

| • | Complete CY 9011 with data supportive of advancing CK-586 to Phase